Search

Background/Aim. In the past three decades, focal segmental glomerulosclerosis (FSGS) was commonly regarded as a part of obesity-related glomerulopathy (ORG), a distinct entity featuring proteinuria, glomerulomegaly, progressive glomerulosclerosis, and a decline of renal function. The present study aimed to evaluate the glomerular morphometry, clinical features, and a two-year outcome in the obese and non-obese FSGS patients. Methods. The study included 35 FSGS patients (23 males, aged 46.5 ± 15.2 years) divided into two groups: obese [body mass index (BMI) = 27 kg/m2 (18 patients, aged 47.2 ± 15.5 years)] and non-obese [BMI < 27 kg/m2 (17 patients, aged 45.7 ± 15.2 years)]. The serum concentrations of proteins, albumin, cholesterol, triglyceride, and creatinine were determined at the time of the biopsy, and 6, 12, and 24 months after the biopsy. Cockcroft-Gault (BMI < 27 kg/m2) and Cockcroft-GaultLBW (BMI = 27 kg/m2) formulas were calculated. Glomerular radius (GR), glomerular volume (GV), and glomerular density (GD) were compared morphometrically between the two groups. Results. At the time of the kidney biopsy and 6 months later, the obese had significantly lower glomerular filtration rate (GFR) compared to the non-obese. After 24 months of follow-up, there were not any differences between the groups. The obese had a significantly higher GR (109.44 ± 6.03 µm vs. 98.53 ± 14.38 µm) and GV (3.13 ± 0.49 × 106 µm3 vs. 2.26 ± 0.83 × 106 µm3), and only slightly lower GD (1.91 ± 0.39/mm2 vs. 1.95 ± 0.61/mm2) compared to the non-obese. A significant positive association between GV and BMI (r = 0.439) was found. After 12 months of follow-up, a significantly higher percentage of the non-obese patients reached complete remission compared to the obese (71.4% vs. 37.5%, respectively; p = 0.041), but after 24 months there were no significant differences. Conclusion. Obese patients, at the time of the kidney biopsy and 6 months later, had already a significantly lower kidney function compared to the non-obese ones. However, 12 and 24 months after, this difference was not statistically significant. Also, 24 months after, there was no significant difference between the two groups in the percentage of patients with complete remission of the nephrotic syndrome. [ABSTRACT FROM AUTHOR]

Background/Aim. Different surgical interventions have been proposed, including trabeculectomy associated with antiproliferative agents because silicone oil (SO) removal cannot necessarily provide intraocular pressure (IOP) control. The aim of the study was to determine the efficacy of trabeculectomy with mitomycin C (MMC) for lowering IOP in patients with open-angle glaucoma (OAG) secondary to emulsified SO after pars plana vitrectomy. Methods. A single-center, prospective study was conducted, from December 2014 to December 2019, on 56 consecutive patients with an uncontrolled elevation of IOP after SO removal who were subjected to trabeculectomy with mitomycin MMC in that period. The primary end-point was the IOP at the three-year follow-up visit. Complete surgical success was defined as an IOP ranging from 7 mmHg to 18 mmHg without glaucoma medication. Qualified success was defined as I OP = 2 1 m mHg with one or two topical medications. Results. Fifty-six patients with a mean age of 5 3.6 [standard deviation (SD)15.5] years had a mean baseline IOP of 42.3 (39.3 to 45.3) mmHg, which reduced to 18.6 (17.9 to 19.3) mmHg three years after surgery (p < 0.0001). Seventeen (30.4%) eyes were classified as a complete success, 21 (37,5%) as a qualified success, and 18 (32.1%) as a failure. In all successfully treated patients, the number of antiglaucoma medications was significantly reduced from 2.85 (SD 0.77) to 1.63 (SD 0.62), p < 0.0001. Conclusion. Trabeculectomy with MMC may be an option for lowering IOP in patients with OAG secondary to emulsified SO after pars plana vitrectomy, which was not controlled with maximum antiglaucomatous medical treatment. [ABSTRACT FROM AUTHOR]